Heart BMJ

AUGUST 26, 2024

Background Cardiac magnetic resonance (CMR) allows comprehensive myocardial tissue characterisation, revealing areas of myocardial inflammation or fibrosis that may predispose to ventricular arrhythmias (VAs). Conclusion CMR is a valuable tool in the diagnostic and prognostic evaluation of patients with VAs.

Arrhythmia 96

Arrhythmia Cardiomyopathy Heart Disease Tachycardia 96

Cardiomatics

APRIL 5, 2024

By understanding the nuances of abnormalities detected in Cardiomatics and interpreting detailed reports, healthcare professionals can intervene promptly to prevent adverse outcomes. Other times, an irregular recording can signal a medical emergency, such as a myocardial infarction or a dangerous arrhythmia.

Arrhythmia 92

Arrhythmia Tachycardia Bradycardia Electrocardiogram 92

Circulation: Cardiovascular Interventions

MARCH 9, 2025

However, the impact of nickel hypersensitivity on post-procedural outcomes remains poorly understood. No significant differences were observed in documented arrhythmias, bleeding, or stroke. These findings highlight the need for further research to optimize device selection and improve outcomes in nickel-hypersensitive patients.

Chest Pain 70

Chest Pain Cardiovascular Interventions Document Arrhythmia 70

Open Heart

MARCH 22, 2025

Introduction Atrial fibrillation is the most prevalent sustained arrhythmia worldwide and is expected to increase substantially within the coming years. Eligible patients are randomised 1:1 to either a combined supervised and eHealth-based exercise intervention or usual care for 12 months.

Atrial Fibrillation 52

Atrial Fibrillation Exercise Quality of Life Document 52

Journal of Cardiovascular Electrophysiology

MARCH 17, 2025

Distribution Variance of Focal Atrial Tachycardia Foci and Long-Term Outcomes After Ablation. Multivariate Cox regression analysis suggested that multifocal ablation (HR: 3.055, 95% CI: 1.4766.323) and NT-proBNP (per standard deviation, HR: 1.367, 95% CI: 1.1571.614) were independently associated with arrhythmia recurrence after ablation.

Tachycardia 40

Tachycardia Ablation Outcomes Tricuspid 40

Science Daily - Heart Disease

APRIL 26, 2024

However, the risk of arrhythmias following this procedure is reportedly high. The highly positive outcomes observed in primate models highlight the potential of this strategy. Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function.

Transplant 125

Transplant Arrhythmia Research Outcomes 125

Journal of Cardiovascular Electrophysiology

NOVEMBER 29, 2023

However, the incidence of ventricular arrhythmias (VAs) is high in this population, both in the acute and delayed phases after implantation. About one-third of patients implanted with an LVAD will experience sustained VAs, predisposing these patients to worse outcomes and complicating patient management.

Arrhythmia 75

Arrhythmia Heart Failure Ablation Outcomes 75

HeartRhythm

APRIL 30, 2024

arrhythmias are common in pregnant women. However, data of clinical signs, course of pregnancy, obstetric and neonatal outcomes is limited.

Arrhythmia 40

Arrhythmia Outcomes 40

Frontiers in Cardiovascular Medicine

OCTOBER 9, 2024

The primary outcome was ventricular arrhythmias, the secondary outcomes were bradycardia and atrial fibrillation (AF).ResultsOur Perioperative or postoperative use of DEX reduced the incidence of in-hospital ventricular arrhythmias [Odds Ratio (OR) 0.14, 95% Confidence Interval (CI) 0.03–0.66],

Arrhythmia 52

Arrhythmia Bradycardia Atrial Fibrillation Hospital 52

American College of Cardiology

FEBRUARY 19, 2025

In this weeks View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrial fibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis.

Arrhythmia 53

Arrhythmia Cardiomyopathy Ablation AFIB 53

HeartRhythm

APRIL 30, 2024

Arrhythmias are common in patients with hypertrophic cardiomyopathy (HCM) and are associated with increased morbidity and mortality. Ventricular arrhythmias (VA) are less common compared to supraventricular arrhythmias yet are associated with worse outcomes in this patient population.

Arrhythmia 40

Arrhythmia Cardiomyopathy Ablation Outcomes 40

HeartRhythm

AUGUST 13, 2024

Atrial arrhythmias (AA), particularly atrial fibrillation (AF), are prevalent in CA and may impact long-term cardiovascular outcomes, prompting an investigation into early rhythm management strategies.2 1 Recent advancements in imaging and therapeutic agents have sparked considerable interest in this field.

Arrhythmia 40

Arrhythmia Ablation Atrial Fibrillation Outcomes 40

HeartRhythm

APRIL 30, 2024

Stereotactic arrhythmia radioablation (STAR) is used as a rescue treatment for refractory ventricular tachycardia (VT) following unsuccessful radiofrequency catheter ablation (RFCA). The mid-term outcomes of STAR, however, remain poorly known.

Tachycardia 40

Tachycardia Arrhythmia Outcomes Ablation 40

HeartRhythm

APRIL 30, 2024

Ventricular tachycardia (VT) ablation in structural heart disease improves arrhythmia free survival. Procedural factors that influence these outcomes are not well described.

Arrhythmia 40

Arrhythmia Ablation Electrophysiology Outcomes 40

Open Heart

SEPTEMBER 28, 2022

Objectives Examine the association between arrhythmias and adverse maternal outcomes in women with structurally normal hearts. Arrhythmia was previously diagnosed in 58.0% After adjusting for age, parity and comorbidities, the presence of any arrhythmia was an independent predictor of CS (OR 1.7 AF and 8.1% 95% CI 1.2

Arrhythmia 52

Arrhythmia Tachycardia Atrial Fibrillation Outcomes 52

HeartRhythm

OCTOBER 7, 2024

Arrhythmias can lead to cardiac arrest (CA) and heart failure. When intractable, heart transplant (HTX) can become the only viable treatment. This rare, high-risk cohort has not been reported as a distinct group.

Heart Transplant 40

Heart Transplant Transplant Arrhythmia Cardiac Arrest 40

American College of Cardiology

FEBRUARY 20, 2024

What are the outcomes of the stellate ganglion block (SGB) with respect to recurrence of ventricular tachycardia/ventricular fibrillation (VT/VF)?

Arrhythmia 65

Arrhythmia Tachycardia Outcomes Article 65

HeartRhythm

APRIL 30, 2024

The overall prevalence of arrhythmias in pregnancy is estimated at 68-166 per 100,000 pregnancy-related admissions. Arrhythmias in pregnancy are thought to be multifactorial in nature due to a combination of hemodynamic, hormonal and autonomic changes that occur during pregnancy.

Arrhythmia 40

Arrhythmia Outcomes 40

DAIC

APRIL 8, 2025

FDA Breakthrough Medical Device Designation Prior to this FDA clearance, ViaOne had already received and was taking part in the FDAs prestigious Breakthrough Device Designation (BDD) program, recognizing its potential to deliver more effective treatments for patients with complex cardiac arrhythmias.

Electrophysiology 52

Electrophysiology Arrhythmia Innovation Technology 52

Journal of Cardiovascular Electrophysiology

FEBRUARY 21, 2024

The impact of supraventricular arrhythmias on the outcomes of guideline-compliance implantable cardioverter defibrillators programming. A greater magnitude of reduced ICD therapy was found in those with supraventricular arrhythmias.

Defibrillator 40

Defibrillator Arrhythmia Outcomes Article 40

Nature Reviews - Cardiology

FEBRUARY 27, 2024

Nature Reviews Cardiology, Published online: 28 February 2024; doi:10.1038/s41569-024-01004-2 Atrial fibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers.

Atrial Fibrillation 107

Atrial Fibrillation Arrhythmia Outcomes 107

Journal of the American Heart Association

FEBRUARY 3, 2025

Cardiac PDE2transgenic mice are protected against contractile dysfunction and arrhythmias in heart failure but whether an acute elevation of PDE2 could be of therapeutic value remains elusive. Journal of the American Heart Association, Ahead of Print. BackgroundPDE2 (phosphodiesterase 2) is upregulated in human heart failure.

Heart Failure 49

Heart Failure Arrhythmia Outcomes 49

HeartRhythm

JULY 9, 2024

However, cardiac arrhythmias remain a significant concern with their use. Bruton Tyrosine Kinase inhibitors (BTKi) have emerged as a standard of care option for patients with chronic lymphocytic leukemia (CLL). For example, atrial fibrillation (AF) is the most common cause of discontinuation of treatment with ibrutinib.

Arrhythmia 40

Arrhythmia Atrial Fibrillation Outcomes 40

Frontiers in Cardiovascular Medicine

FEBRUARY 5, 2025

IntroductionAtrial fibrillation (AF) is a prevalent cardiac arrhythmia and a significant contributor to cardioembolic stroke, a condition closely linked to cognitive decline. However, research reveals that AF itself is independently associated with an increased risk of cognitive impairment.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Arrhythmia Research 52

Heart BMJ

MAY 10, 2024

Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Arrhythmia prediction models have long relied on conventional risk factors such as age, diabetes, hypertension, and history of myocardial infarction and heart failure.

Arrhythmia 40

Arrhythmia Myocardial Infarction Atrial Fibrillation Heart Failure 40

The American Journal of Cardiology

JUNE 11, 2024

Publication date: Available online 11 June 2024 Source: The American Journal of Cardiology Author(s): Steven Brady, Eldon Matthia, Steve Antoine, Juan Aranda, William Miles, Juan Vilaro, Mohammad Al-Ani, Olusola Oduntan, Yi Guo, Yujia Li, Mustafa Ahmed, Alex Parker

Heart Failure 52

Heart Failure Arrhythmia Outcomes 52

Circulation: Arrhythmia and Electrophysiology

APRIL 17, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Epicardial radiofrequency catheter ablation (RFCA) of idiopathic ventricular arrhythmias (VAs) originating from the left ventricular summit (LVS) is challenging because of the anatomic barriers.

Arrhythmia 45

Arrhythmia Ablation Electrophysiology Outcomes 45

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2025

Baseline characteristics, procedural details, and clinical outcomes were compared between the groups.ResultsA total of 189 patients [65.0 months, the recurrence rates of arrhythmias were significantly lower in the AFT group (log-rank P=0.044). Propensity score matching (PSM) was applied to eliminate covariate imbalances.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Arrhythmia Outcomes 52

Frontiers in Cardiovascular Medicine

JULY 8, 2024

BackgroundHuman pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) show tremendous promise for cardiac regeneration following myocardial infarction (MI), but their transplantation gives rise to transient ventricular tachycardia (VT) in large-animal MI models, representing a major hurdle to translation.

Pacemaker 52

Pacemaker CMS Arrhythmia Transplant 52

Circulation

NOVEMBER 11, 2024

Ischemic cardiomyopathy, a severe cardiac condition resulting from prolonged myocardial ischemia, is characterized by ventricular dilation, dysfunction, and an increased risk of life-threatening arrhythmias. Arrhythmia, a common complication in ischemic cardiomyopathy, is associated with poor clinical outcomes.

Arrhythmia 40

Arrhythmia Cardiomyopathy Ischemia Circulation 40

HeartRhythm

APRIL 30, 2024

Treatment-refractory ventricular arrhythmias (VA) are commonly driven by heightened sympathetic tone. Sympathetic modulation by percutaneous stellate ganglion block (SGB) is an emerging modality to achieve short-term reduction in VA burden with few adverse events.

Arrhythmia 40

Arrhythmia Outcomes 40

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The primary outcome was a clinical recurrence of documented atrial arrhythmias for >30 s during the 1-year follow-up.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

HeartRhythm

APRIL 30, 2024

Atrial arrhythmias (AA) are common in patients with pulmonary disease and various cancers. However, the association between AA and non-small cell lung cancer (NSCLC), and the impact of AA on overall clinical outcome in patients with NSCLC are not well-known.

Cancer 40

Cancer Arrhythmia Pulmonary Outcomes 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background Programed ventricular stimulation (PVS) is a risk stratification tool in patients at risk for adverse arrhythmia outcomes. Patients with negative PVS may yet be at risk for adverse arrhythmia-related events, particularly in the presence of symptomatic ventricular arrhythmias (VA).

Arrhythmia 40

Arrhythmia Outcomes Bradycardia Bicuspid/Mitral 40

HeartRhythm

JULY 14, 2024

high blood pressure) as instrumental variables to test causal effects on an outcome (e.g., We screened 391 papers, examining 278 that applied MR to investigate arrhythmia and, among others, cardiovascular traits, lifestyle, behavioral traits, body composition. atrial fibrillation (AF)).

Arrhythmia 40

Arrhythmia Blood Pressure Atrial Fibrillation Outcomes 40

HeartRhythm

JANUARY 7, 2025

Patients with D-transposition of the great arteries (D-TGA) palliated with atrial switch often develop atrial arrhythmias (AA) requiring pulmonary venous atrium (PVA) access for ablation, which can be achieved via retrograde aortic approach (RAA) or trans-baffle access (TBA).13

Arrhythmia 45

Arrhythmia Aortic Ablation Pulmonary 45

Journal of Cardiovascular Electrophysiology

OCTOBER 14, 2024

Ablation index (AI) and generator impedance drop (ID) predict lesion size but their correlation with long-term outcomes in prAF is not known. Analyzed as continuous variables, ID and ER predicted long-term arrhythmia-free survival but not AI. It predicted reduced risk of arrhythmia: hazard ratio 0.56 [0.360.88], p =.013

Arrhythmia 40

Arrhythmia Ablation Atrial Fibrillation Outcomes 40